The Chloride Channel Protein 1 pipeline drugs market research report outlays comprehensive information on the Chloride Channel Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Chloride Channel Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Musculoskeletal Disorders, Immunology, and Genetic Disorders which include the indications Neuromuscular Disorders, Spinal Muscular Atrophy (SMA), Sarcopenia, Myasthenia Gravis, Charcot-Marie-Tooth Disease Type I, and Charcot-Marie-Tooth Disease Type II. It also reviews key players involved in Chloride Channel Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Chloride Channel Protein 1 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 2, 1, and 3 respectively.
Chloride Channel Protein 1 overview
Chloride Channel Protein 1 (CLCN1) is a voltage-gated chloride channel that plays a crucial role in regulating the movement of chloride ions across cell membranes. It is primarily expressed in skeletal muscle fibers, where it facilitates the rapid repolarization of muscle cells following contraction, enabling efficient muscle function. CLCN1 is a homodimeric protein, meaning it consists of two identical subunits that assemble to form a functional chloride channel. Each subunit harbors an independent chloride-conducting pore, allowing CLCN1 to function as a “double-barrel” channel, enhancing its chloride transport capacity.
For a complete picture of Chloride Channel Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
